AbbVie Inc (ABBV) Balance Sheet

A balance sheet shows what a company owns and owes, and shareholders' equity, at a single point in time.

AbbVie Inc., a research-based biopharmaceutical company, engages in the research and development, manufacturing, commercializing, and sale of medicines and therapies worldwide.

Total Assets Chart for AbbVie Inc

AbbVie Inc (ABBV) total assets for FY2025 were USD 134.0B, a -0.9% change from FY2024. AbbVie Inc's total assets grew from USD 21.1B in 2010 to USD 134.0B in 2025 (533.8% over 15 years). Total assets compound annual growth rate: 5-year CAGR of -2.3%, 10-year CAGR of 9.7%.

The most recent 3 years are real; the rest is blurred as a preview. Sign up free to unlock every line item, quarterly data, and the real full history. Free account: 8 years of history for 10 flagship companies. Premium: full history for 500+ companies. Premium is €10.00/month. See pricing.

Total Assets (US Dollars)

R&D as % of Revenue

Compare with

Key Stats

Market Cap
$430.95B
Implied Share Price
$243.87
Enterprise Value
$506.83B
Revenue (TTM)
$64.39B
EBITDA
$30.76B
Profit Margin
9.80%
Trailing P/E
69.48
Forward P/E
17.79
Price/Book (MRQ)
50.46
Price/Sales (TTM)
6.69
EV/EBITDA
44.16
EV/Revenue
7.87
Dividend Yield
2.77%
Book Value
$-3.36
Free Cash Flow (FY2025)
$17.82B
Free Cash Flow Yield
4.13%

Snapshot as of 7th August 2026 — not point-in-time controlled, may lag the live market by a few days.